Bexmarilimab Derives Overall Survival Benefit in PD-1 Blockade Refractory Melanoma
Source: Targeted Oncology, October 2022
Results from the melanoma cohort of the phase 1/2 MATINS show the potential of bexmarilimab monotherapy and combined with other immunotherapies across solid tumors and hematologic malignancies.
Findings from the ongoing phase 1/2 MATINS trial revealed there to be a clinical benefit derived bexmarilimab (FP-1305) with 100% overall survival (OS) at 12-months in patients with PD-1 blockade refractory melanoma patients, according to Faron Pharmaceuticals Ltd.1
Patients who had cold tumors, defined by low baseline levels of pro-inflammatory cytokines, were more likely to have clinical benefit with bexmarilimab. For the patients who derived benefit from bexmarilimab, they had a seven-fold increase in serum interferon gamma (IFN?). This suggests that retreatment with anti-PD-1 could be beneficial.